Eli Lilly & Co. (LLY)

78.75
NYSE : Health Technology
Prev Close 77.19
Day Low/High 77.64 / 78.86
52 Wk Low/High 73.69 / 89.09
Avg Volume 4.23M
Exchange NYSE
Shares Outstanding 1.10B
Market Cap 84.96B
EPS -0.20
P/E Ratio N/A
Div & Yield 2.25 (2.68%)

Latest News

Last Week's Portfolio Updates

Initiations/Exits, Price Target Updates and Ratings Changes are all here.

Survey Reveals Many People With Migraine Live With Pain Nearly Half Of Every Month

Survey Reveals Many People With Migraine Live With Pain Nearly Half Of Every Month

- Migraine Impact Report highlights physical, social and economic challenges of migraine -

AAD 2018: Treatment With Lilly's Taltz® (ixekizumab) Resulted In Improvement In Impact Of Genital Psoriasis On Sexual Activity

AAD 2018: Treatment With Lilly's Taltz® (ixekizumab) Resulted In Improvement In Impact Of Genital Psoriasis On Sexual Activity

- Reductions in the impact of genital psoriasis on sexual activity seen as early as one week -

Weekly Roundup

Markets rebound this week.

Jim Cramer: Drug Stocks on the Move

Jim Cramer: Drug Stocks on the Move

We could be poised for even a further advance PROVIDED that we stay oversold.

Here's How Eli Lilly Stock Can Regain Its Footing

Here's How Eli Lilly Stock Can Regain Its Footing

Watch these key price levels on LLY.

Lilly To Showcase New Data For Taltz® (ixekizumab) And Other Products Across Immunology Pipeline At AAD Annual Meeting

Lilly To Showcase New Data For Taltz® (ixekizumab) And Other Products Across Immunology Pipeline At AAD Annual Meeting

- 14 abstracts include data for Taltz in genital psoriasis, baricitinib in atopic dermatitis and mirikizumab in plaque psoriasis -

Intermediate Trade: Eli Lilly

Intermediate Trade: Eli Lilly

Consider this LLY out of the money, bullishly biased vertical call spread expiring in April.

Adding to Lilly and Upgrading Rating

We are essentially buying back the shares we recently sold -- at a large discount.

Weekly Roundup

Markets extend losses in volatile week.

Why Investors Shouldn't Worry About Trump's Tough Talk on Drug Prices

Why Investors Shouldn't Worry About Trump's Tough Talk on Drug Prices

While Donald Trump's tweets can shake up pharmaceutical stocks, history suggests that investors have little to fear from the president's drug pricing rhetoric.

We Are Buyers Down at These Levels

Nothing has changed with fundamentals, so 'good names' have gone on sale.

Pharma Execs Talk M&A, Drug Pricing Pressures on Earnings Calls

Pharma Execs Talk M&A, Drug Pricing Pressures on Earnings Calls

'I think everybody is looking at potential combinations and consolidations,' Pfizer CEO Ian Read said on an earnings call on Tuesday, Jan. 30.

It's Bad, but It's Not a Crash: Cramer's 'Mad Money' Recap (Friday 2/2/18)

It's Bad, but It's Not a Crash: Cramer's 'Mad Money' Recap (Friday 2/2/18)

In a special edition of Mad money, Jim Cramer examines this brutal decline and lays out the game plan for next week -- live from Minneapolis ahead of the Super Bowl.

Shopify, Kinder Morgan, Pfizer: 'Mad Money' Lightning Round

Shopify, Kinder Morgan, Pfizer: 'Mad Money' Lightning Round

Jim Cramer highlights Shopify, Kinder Morgan, Thermo Fisher Scientific, Radius Health, Merck, Pfizer and more.

Weekly Roundup

Big market selloff

It's a Flash Sale!: Cramer's 'Mad Money' Recap (Wednesday 1/31/18)

It's a Flash Sale!: Cramer's 'Mad Money' Recap (Wednesday 1/31/18)

Jim Cramer explains how to rely on long-term themes to take advantage of this market's wild action.

Dow, S&P 500 and Nasdaq Finish Higher After Up-and-Down Day of Trading

Dow, S&P 500 and Nasdaq Finish Higher After Up-and-Down Day of Trading

Stocks rebounded on Wednesday.

Noteworthy Wednesday Option Activity: LLY, AVHI, CASC

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Lilly (Eli) & Co , where a total of 22,032 contracts have traded so far, representing approximately 2.2 million underlying shares. That amounts to about 52.3% of LLY's average daily trading volume over the past month of 4.2 million shares.

Jim's Daily Rundown

Jim discusses the State of the Union and how it relates to defense and Nucor, the Amazon-JPMorgan-Berkshire Hathaway news, Lilly's quarter, Facebook and Microsoft.

Eli Lilly Beats Estimates, but Shares Head Lower Amid Diabetes Concerns

Eli Lilly Beats Estimates, but Shares Head Lower Amid Diabetes Concerns

BMO Capital Markets analyst Alex Arfaei says the fourth-quarter results show how dependent the drugmaker is on major diabetes assets 'and doesn't alleviate our concerns.'

Eli Lilly Beats Estimates, Raises Guidance

Pharmaceutical maker sees strong growth in new products.

Jim Cramer: I Wish Some Stocks Would Not Keep Rallying

Jim Cramer: I Wish Some Stocks Would Not Keep Rallying

Facebook is making itself a tough own ahead of the quarterly results.

Boeing's Blowout Q4 Sparks Wall Street Futures Rebound After Vicious Market Rout

Boeing's Blowout Q4 Sparks Wall Street Futures Rebound After Vicious Market Rout

Wall Street futures surged Wednesday following the biggest two-day decline since September 2016, powered in part by a record set of annual results for the world's biggest planemaker.

Big Pharma and the Sellers of Its Products Now Have a Problem

Big Pharma and the Sellers of Its Products Now Have a Problem

Who, out there in the health care sector, is safe?

Dow, Trump, AMD, Xerox and Apple - 5 Things You Must Know

Dow, Trump, AMD, Xerox and Apple - 5 Things You Must Know

U.S. stock futures suggest Wall Street will rebound on Wednesday, following the biggest two-day decline on Wall Street in more than two year.

Jim's Daily Rundown

Jim discusses an analyst upgrade of Allergan, the super cycle concerns of Apple and how it impacts Broadcom, defense names in the bullpen, and a busy week of earnings.

TheStreet Quant Rating: B (Buy)